2024年基层医生应关注的20项研究
本文汇总2024年20项以患者为导向的重要证据(POEM)。涉及社区获得性肺炎口服抗生素选择、COVID-19抗病毒治疗、呼吸道合胞病毒预防、鼻窦炎和疥疮治疗、尿路感染益生菌预防、肠易激综合征二线治疗、胆结石保守管理、糖尿病及减重药物疗效、心血管二级预防、戒烟策略、酒精使用障碍治疗、长新冠疲劳认知行为治疗及阿尔茨海默病单抗安全性等。
要点
- 社区获得性肺炎口服抗生素中,阿奇霉素、阿莫西林-克拉维酸和部分喹诺酮类可能有效。
- SGLT-2抑制剂和GLP-1受体激动剂改善2型糖尿病以患者为导向的结局优于旧药。
- 伐尼克兰或联合尼古丁替代疗法未戒烟者,增加剂量可提高戒烟率。
核心结论
- 多项研究为基层常见病管理提供了以患者为导向的证据,涉及抗感染、慢病、戒烟和心理健康等领域。
- 部分新药或新策略显示获益,而连续血糖监测和阿尔茨海默病单抗等则提示需谨慎评估。
研究设计与样本
- 本文为2024年POEMs(以患者为导向的重要证据)前20项研究的汇总,基于网络荟萃分析及多项临床研究。
主要发现
- 社区获得性肺炎口服抗生素中,替利霉素(美国不可用)、阿奇霉素、阿莫西林-克拉维酸及左氧氟沙星和奈诺沙星(美国不可用)可能有效。
- 莫努匹韦和奈玛特韦-利托那韦减少免疫功能低下COVID-19患者住院。
- 平均风险婴儿单剂尼塞韦单抗减少呼吸道合胞病毒住院。
- 阿莫西林(联合或不联合克拉维酸)对儿童急性鼻窦炎症状优于安慰剂。
- 25%苯甲酸苄酯对青少年和成人疥疮高度有效。
关键数值与推荐
- 含乳杆菌益生菌减少绝经前频繁尿路感染女性复发。
- 低剂量阿米替林是肠易激综合征有效二线治疗。
- 无并发症胆结石保守管理是合理选择。
- SGLT-2抑制剂和GLP-1受体激动剂改善2型糖尿病以患者为导向的结局优于旧药。
- 连续或间歇血糖监测对2型糖尿病控制效果甚微且可能有害。
临床怎么用
- 基层医生可依据这些证据优化社区获得性肺炎、鼻窦炎、疥疮和尿路感染的治疗选择。
- 2型糖尿病合并心衰老年患者可考虑SGLT-2抑制剂或GLP-1受体激动剂以降低心血管死亡。
- 戒烟失败者可尝试增加伐尼克兰或联合尼古丁替代疗法剂量。
- 长新冠疲劳可考虑认知行为治疗。
- 阿尔茨海默病新单抗有害、昂贵且效果有限,需谨慎使用。
局限性
- 本文为研究汇总,未报告各项研究的样本量、置信区间和P值等详细数据。
- 部分药物(替利霉素、奈诺沙星)在美国不可用,适用性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article summarizes the top 20 research studies of 2024 identified as POEMs (patient-oriented evidence that matters). Based on a network meta-analysis, the oral antibiotics most likely to be effective for community-acquired pneumonia are telithromycin (not available in the United States), azithromycin, amoxicillin-clavulanate, and the quinolones levofloxacin and nemonoxacin (not available in the United States). The oral antivirals molnupiravir and nirmatrelvir-ritonavir reduce hospitalizations in immunocompromised patients with COVID-19. In average-risk infants, a single dose of nirsevimab reduces hospitalizations due to respiratory syncytial virus. Amoxicillin with or without clavulanate is more effective than placebo for children with symptoms of acute sinusitis. Benzyl benzoate 25% is highly effective for scabies in adolescents and adults. Lactobacillus-containing probiotics reduce the incidence of recurrent urinary tract infections (UTIs) in premenopausal women with frequent UTIs. Low-dose amitriptyline is effective as second-line therapy for irritable bowel syndrome. For patients with uncomplicated gallstones, conservative management is a reasonable option. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are better than older drugs at improving patient-oriented outcomes for type 2 diabetes. Continuous or intermittent glucose monitoring is minimally effective for control of type 2 diabetes and can be harmful. Phentermine-topiramate and GLP-1 receptor agonists are the most effective drugs for promoting weight loss. Semaglutide is effective for secondary prevention of cardiovascular disease in people with obesity and no diabetes. SGLT-2 inhibitors and GLP-1 receptor agonists decrease cardiovascular death in older adults with type 2 diabetes and heart failure. Beta blockers do not prevent subsequent events after myocardial infarction in patients with preserved ejection fraction. For patients who do not quit smoking after a trial of varenicline or combined nicotine replacement therapy, a higher dose of either drug can increase quit rates. e-Cigarettes increase abstinence from smoking, but long-term vaping is a consequence for some. Oral naltrexone and acamprosate are safe and effective treatments for alcohol use disorder. Cognitive behavior therapy can reduce fatigue attributed to long COVID. New monoclonal antibodies for Alzheimer disease are harmful, expensive, and minimally effective. Clinicians may choose to deliver bad news in person or by telephone, using their judgment or patient preference to decide which is best for the patient.
引用
- Grad R, Ebell MH. Top 20 Research Studies of 2024 for Primary Care Physicians. Am Fam Physician. 2025. PMID: 40736492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。